Literature DB >> 23605439

Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma.

Hiroki Goto1, Yuki Kojima, Hirokazu Nagai, Seiji Okada.   

Abstract

Primary effusion lymphoma (PEL) presents as a serous lymphomatous effusion without tumor masses exclusively in body cavities and mainly occurs in human immunodeficiency virus-1 (HIV-1)-infected patients. We established a new PEL cell line, designated GTO, from the pericardial effusion of a 39-year-old Japanese patient with acquired immunodeficiency syndrome-related PEL. This cell line was infected with human herpesvirus-8, but not with Epstein-Barr virus. Southern blot hybridization demonstrated that GTO cells display monoclonal rearrangement of the IgH gene, suggesting clonal B cell proliferation. GTO cells weakly express or lack T cell-associated markers (CD3, CD5, CD8), the majority of B cell-associated markers (CD19, CD20, CD21, CD79a), the α chains of β 2 integrins (CD11a, CD11b, CD11c), HLA-DR, CD30, and surface immunoglobulin (sIgM, sIgG sIgκ, sIgλ), TCR (α/β, γδ), but express CD45, and post-germinal center B cell/plasma cell-associated antigens (CD38, CD138). They also express a high level of cell-surface CD4 and can be infected by HIV-1. Immunodeficient mice intraperitoneally xenografted with GTO cells developed ascites containing lymphoma cells. The establishment of GTO and a GTO xenograft mouse model may help to provide insights toward a better understanding of the pathogenesis of PEL and the relationship between HIV-1 and HHV-8.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605439     DOI: 10.1007/s12185-013-1339-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  45 in total

1.  Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma.

Authors:  H Katano; Y Hoshino; Y Morishita; T Nakamura; H Satoh; A Iwamoto; B Herndier; S Mori
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

2.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

3.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

4.  RNAs in the virion of Kaposi's sarcoma-associated herpesvirus.

Authors:  Jill Bechtel; Adam Grundhoff; Don Ganem
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma.

Authors:  H Katano; T Iwasaki; N Baba; M Terai; S Mori; A Iwamoto; T Kurata; T Sata
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

7.  The tumor microenvironment controls primary effusion lymphoma growth in vivo.

Authors:  Michelle R Staudt; Yogita Kanan; Joseph H Jeong; James F Papin; Rebecca Hines-Boykin; Dirk P Dittmer
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

8.  EBV is necessary for proliferation of dually infected primary effusion lymphoma cells.

Authors:  Amanda A Mack; Bill Sugden
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

9.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

10.  Midkine as a prognostic biomarker in oral squamous cell carcinoma.

Authors:  K Ota; H Fujimori; M Ueda; S Shiniriki; M Kudo; H Jono; Y Fukuyoshi; Y Yamamoto; H Sugiuchi; H Iwase; M Shinohara; Y Ando
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

View more
  5 in total

1.  Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.

Authors:  H Goto; R Kariya; E Kudo; Y Okuno; K Ueda; H Katano; S Okada
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

2.  Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.

Authors:  Jutatip Panaampon; Ryusho Kariya; Seiji Okada
Journal:  Cancer Immunol Immunother       Date:  2022-03-09       Impact factor: 6.630

3.  Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion.

Authors:  Anna Friis; Börje Akerlund; Birger Christensson; Katarina Gyllensten; Anna Aleman; Jie-Zhi Zou; Ingemar Ernberg
Journal:  Infect Agent Cancer       Date:  2013-07-23       Impact factor: 2.965

4.  Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus.

Authors:  Madori Osawa; Sohtaro Mine; Shinichiro Ota; Kengo Kato; Tsuyoshi Sekizuka; Makoto Kuroda; Michiyo Kataoka; Hitomi Fukumoto; Yuko Sato; Takayuki Kanno; Hideki Hasegawa; Keiji Ueda; Masashi Fukayama; Takuya Maeda; Soichiro Kanoh; Akihiko Kawana; Yuji Fujikura; Harutaka Katano
Journal:  Infect Agent Cancer       Date:  2016-08-17       Impact factor: 2.965

5.  KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo.

Authors:  Pirita Pekkonen; Annika Järviluoma; Nadezhda Zinovkina; Anna Cvrljevic; Sonam Prakash; Jukka Westermarck; Gerard I Evan; Ethel Cesarman; Emmy W Verschuren; Päivi M Ojala
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.